Prothena (PRTA) announced that Novo Nordisk (NVO) communicated during their second quarter 2025 earnings call on August 6 that they expect to advance coramitug, a potential amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy in 2025. Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. Under the terms of the agreement, Prothena is eligible to receive up to $1.2B dollars upon achievement of clinical development and sales milestones, including the $100M earned to date. Prothena is eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the Phase 3 clinical trial. Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk
- Prothena’s Strategic Initiatives and Promising Alzheimer’s Pipeline Drive Buy Rating
- Prothena Reports Q2 2025 Financial Results and Pipeline Progress
- Prothena reports Q2 EPS ($2.34), consensus ($1.79)
- PRTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?